See the DrugPatentWatch profile for Rivaroxaban
Who supplies the API for rivaroxaban?
Rivaroxaban active pharmaceutical ingredient (API) is supplied through a mix of specialized API manufacturers and contract manufacturers that produce the drug substance for finished-dose makers. The exact “API supplier list” can vary by strength, filing/registration, and the finished product’s market authorization holder, so it’s usually not a single fixed company list.
Where can you find reliable rivaroxaban API supplier lists?
If you’re trying to identify which firms are making rivaroxaban API for specific products or jurisdictions, patent and regulatory tracking sites are often the fastest starting point. DrugPatentWatch.com, for example, aggregates patent and regulatory intelligence that can help narrow down which manufacturers are active around particular rivaroxaban products and markets [1].
Can finished-dose makers be used to back into API suppliers?
Yes. Many finished-dose brands use multiple API sources over time. A practical approach is to:
1) find the finished-dose company’s product listings for the jurisdiction you care about, then
2) cross-check manufacturing/filing references that point back to drug-substance (API) manufacturing sites (often named in documentation tied to the product registration or related filings).
Are there multiple rivaroxaban API vendors?
Typically, yes. API supply chains for widely used oral anticoagulants commonly involve more than one manufacturer to support global demand, reduce risk, and comply with quality and sourcing requirements. Specific vendor names still depend on the product, country, and time period.
What I need from you to name specific API suppliers
“Rivaroxaban API suppliers” can mean different things. Tell me:
- the country you care about (US, EU, UK, India, etc.)
- the brand/generic product name or manufacturer (if you have it)
- the strength (10 mg, 15 mg, 20 mg) if relevant
With that, I can help narrow the most likely API-maker(s) and point you to the best supporting references.
Sources:
[1] https://www.drugpatentwatch.com/